Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.
Previous PostThe Social Deprivation Index And Deep Brain Stimulation: A Cohort Study
Next PostTelomere Length Analysis of CNS Tumors in the Pediatric Brain Tumor Atlas
